ArticleZoonoses and public health2020
Epidemiology and cost of Lyme disease-related hospitalizations among patients with employer-sponsored health insurance-United States, 2005-2014.
Article in Zoonoses and public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Healthcare claims-based Lyme disease case-finding algorithms in the United States: A systematic literature review.PloS one · 2022Pooled it
- Sex and menopause-based differences in presentation of early Lyme disease: A prospective cohort study.Clinical and experimental medicine · 2026Article
- Long-term Cardiac Sequelae in Lyme Carditis: A Review.Current cardiology reviews · 2026Review
- Validation of Algorithms to Detect Acute and Disseminated Lyme Disease in U.S. Administrative Claims Data.Open forum infectious diseases · 2025Article
- Optimizing identification of Lyme disease diagnoses in commercial insurance claims data, United States, 2016-2019.BMC infectious diseases · 2024Article
- The conneXion between sex and immune responses.Nature reviews. Immunology · 2024Review
- By-degree Health and Economic Impacts of Lyme Disease, Eastern and Midwestern United States.EcoHealth · 2024Article
- Prevalence of five human pathogens in host-seeking Ixodes scapularis and Ixodes pacificus by region, state, and county in the contiguous United States generated through national tick surveillance.Ticks and tick-borne diseases · 2023Article
- Current and future burden from Lyme disease in Québec as a result of climate change.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2023Article
- Validation of Claims-Based Algorithm for Lyme Disease, Massachusetts, USA.Emerging infectious diseases · 2023Article
- Longitudinal serum proteomics analyses identify unique and overlapping host response pathways in Lyme disease and West Nile virus infection.Frontiers in immunology · 2022Article
- Patient characteristics, treatment patterns, and outcomes of Rickettsial diseases among a commercially insured population in the United States, 2005-2017.Scientific reports · 2021Article
- Human and Veterinary Vaccines for Lyme Disease.Current issues in molecular biology · 2021Article
- Gene-Specific Sex Effects on Susceptibility to Infectious Diseases.Frontiers in immunology · 2021Review
- What Are the Costs of Diagnostics and Treatment of Lyme Borreliosis in Poland?Frontiers in public health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
An estimated 300,000 cases of Lyme disease occur in the United States annually. Disseminated Lyme disease may result in carditis, arthritis, facial palsy or meningitis, sometimes requiring hospitalization. We describe the epidemiology and cost of Lyme disease-related hospitalizations. We analysed 2005-2014 data from the Truven Health Analytics MarketScan Commercial Claims and Encounters Databases to identify inpatient records associated with Lyme disease based on International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. We estimated the annual number and median cost of Lyme disease-related hospitalizations in the United States in persons under 65 years of age. Costs were adjusted to reflect 2016 dollars. Of 20,983,165 admission records contained in the inpatient databases during the study period, 2,823 (0.01%) met inclusion criteria for Lyme disease-related hospitalizations. Over half of the identified records contained an ICD-9-CM code for meningitis (n = 614), carditis (n = 429), facial palsy (n = 400) or arthritis (n = 377). Nearly 60% of hospitalized patients were male. The median cost per Lyme disease-related hospitalization was $11,688 (range: $140-$323,613). The manifestation with the highest median cost per stay was carditis ($17,461), followed by meningitis ($15,177), arthritis ($13,012) and facial palsy ($10,491). Median cost was highest among the 15- to 19-year-old age group ($12,991). Admissions occurring in January had the highest median cost ($13,777) for all study years. Based on extrapolation to the U.S. population, we estimate that 2,196 Lyme disease-related hospitalizations in persons under 65 years of age occur annually with an estimated annual cost of $25,826,237. Lyme disease is usually treated in an outpatient setting; however, some patients with Lyme disease require hospitalization, underscoring the need for effective prevention methods to mitigate these serious cases. Information from this analysis can aid economic evaluations of interventions that prevent infection and advances in disease detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.